Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN

(AMGN)
  Report  
Real-time Quote. Real-time Cboe BZX - 08/20 12:52:17 pm
204.095 USD   -0.92%
08/14AMGEN : Board of Directors Tours Company Labs in San Francisco
PU
08/14AMGEN : Foundation Honors David Baltimore With Gift to Caltech
PU
08/14AMGEN : Ex-dividend day for
FA
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2019 08/15/2019 08/16/2019 08/19/2019 08/20/2019 Date
198.87(c) 199.31(c) 204.02(c) 206(c) 204.39 Last
4 533 821 3 105 128 3 004 345 2 974 913 1 158 756 Volume
-3.52% +0.22% +2.36% +0.97% -0.78% Change
More quotes
Financials (USD)
Sales 2019 22 830 M
EBIT 2019 10 915 M
Net income 2019 7 711 M
Debt 2019 2 336 M
Yield 2019 2,81%
Sales 2020 23 051 M
EBIT 2020 11 089 M
Net income 2020 8 088 M
Finance 2020 1 119 M
Yield 2020 2,98%
P/E ratio 2019 16,2x
P/E ratio 2020 15,2x
EV / Sales2019 5,51x
EV / Sales2020 5,31x
Capitalization 124 B
More Financials
Company
Amgen is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.9%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc. The United States account for 77.3% of net sales; - other (5.1%):... 
Sector
Pharmaceuticals
Calendar
10/31Earnings Release
More about the company
Surperformance© ratings of Amgen
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN
08/14AMGEN : Board of Directors Tours Company Labs in San Francisco
PU
08/14AMGEN : Foundation Honors David Baltimore With Gift to Caltech
PU
08/14AMGEN : Ex-dividend day for
FA
08/12Health Care Down, But Losses Limited by Lack of Cyclical Exposure -- Health C..
DJ
08/12Amgen and Sysco rise while Viacom and Bank of America fall
AQ
08/12NOVARTIS : Sandoz will appeal District Court of New Jersey ruling in biosimilar ..
AQ
08/12AMGEN : Wins Patent Case on Enbrel
AQ
08/09Wall Street ends down amid more trade woes, high volatility
RE
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
RE
08/09AMGEN : Wins Patent Case On Enbrel® (etanercept)
PR
More news
Analyst Recommendations on AMGEN
More recommendations
Stock Trading Strategies
AMGEN - 2018
Comeback of a rising trend ?
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
03:23aASTRAZENECA : Farxiga clears late-stage heart-failure study
RE
02:26aASTRAZENECA : Farxiga Met Primary Endpoint in Landmark Phase 3 Trial
DJ
08/19ALLERGAN : Form 8.3 - Allergan Plc
DJ
08/19NOVARTIS : to answer U.S. Senate demand for data manipulation details
RE
08/19NOVARTIS : CEO Under Fire Over Drug Data
DJ
More sector news : Pharmaceuticals - NEC
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 209,76  $
Last Close Price 206,00  $
Spread / Highest target 12,1%
Spread / Average Target 1,83%
Spread / Lowest Target -16,0%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
David M. Reese Executive Vice President-Research & Development
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN5.82%123 538
JOHNSON & JOHNSON2.48%346 681
ROCHE HOLDING LTD.12.24%238 299
MERCK AND COMPANY12.80%217 785
NOVARTIS17.81%204 677
PFIZER-19.40%191 651